mundibiopharma limited
mundibiopharma limited Company Information
Company Number
09273949
Website
www.mundipharmaresearch.comRegistered Address
unit 196 cambridge science park, milton road, cambridge, CB4 0AB
Industry
Wholesale of pharmaceutical goods
Telephone
02080909664
Next Accounts Due
September 2024
Group Structure
View All
Shareholders
purdue biopharma l.p. 99.8%
cedar rock investment corporation 0.1%
View Allmundibiopharma limited Estimated Valuation
The estimated valuation range for mundibiopharma limited, derived from financial data as of December 2022 and the most recent industry multiples, is between £180.3m to £655.3m
mundibiopharma limited Estimated Valuation
The estimated valuation range for mundibiopharma limited, derived from financial data as of December 2022 and the most recent industry multiples, is between £180.3m to £655.3m
mundibiopharma limited Estimated Valuation
The estimated valuation range for mundibiopharma limited, derived from financial data as of December 2022 and the most recent industry multiples, is between £180.3m to £655.3m
Get a detailed valuation report, edit figures and unlock valuation multiples.
Mundibiopharma Limited AI Business Plan
In just minutes, we combine Pomanda’s company and industry data with cutting edge Artificial Intelligence to build a comprehensive 27 section business plan. You then have 60 days to tailor the information, decide which sections to include or exclude, and add your own branding logos, images and color scheme to create your perfect plan.
Mundibiopharma Limited Overview
Mundibiopharma Limited is a live company located in cambridge, CB4 0AB with a Companies House number of 09273949. It operates in the wholesale of pharmaceutical goods sector, SIC Code 46460. Founded in October 2014, it's largest shareholder is purdue biopharma l.p. with a 99.8% stake. Mundibiopharma Limited is a established, mega sized company, Pomanda has estimated its turnover at £232.8m with declining growth in recent years.
Upgrade for unlimited company reports & a free credit check
Mundibiopharma Limited Health Check
Pomanda's financial health check has awarded Mundibiopharma Limited a 5 rating. We use a traffic light system to show it exceeds the industry average on 6 measures and has 4 areas for improvement. Company Health Check FAQs
6 Strong
2 Regular
4 Weak
Size
annual sales of £232.8m, make it larger than the average company (£25.5m)
£232.8m - Mundibiopharma Limited
£25.5m - Industry AVG
Growth
3 year (CAGR) sales growth of -10%, show it is growing at a slower rate (4.4%)
-10% - Mundibiopharma Limited
4.4% - Industry AVG
Production
with a gross margin of 23.1%, this company has a comparable cost of product (26.4%)
23.1% - Mundibiopharma Limited
26.4% - Industry AVG
Profitability
an operating margin of 27% make it more profitable than the average company (4%)
27% - Mundibiopharma Limited
4% - Industry AVG
Employees
with 6 employees, this is below the industry average (39)
6 - Mundibiopharma Limited
39 - Industry AVG
Pay Structure
on an average salary of £472.4k, the company has a higher pay structure (£72.4k)
£472.4k - Mundibiopharma Limited
£72.4k - Industry AVG
Efficiency
resulting in sales per employee of £38.8m, this is more efficient (£601.7k)
£38.8m - Mundibiopharma Limited
£601.7k - Industry AVG
Debtor Days
it gets paid by customers after 63 days, this is near the average (59 days)
63 days - Mundibiopharma Limited
59 days - Industry AVG
Creditor Days
its suppliers are paid after 40 days, this is slower than average (28 days)
40 days - Mundibiopharma Limited
28 days - Industry AVG
Stock Days
it holds stock equivalent to 0 days, this is less than average (66 days)
0 days - Mundibiopharma Limited
66 days - Industry AVG
Cash Balance
has cash to cover current liabilities for 16 weeks, this is more cash available to meet short term requirements (11 weeks)
16 weeks - Mundibiopharma Limited
11 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 64.9%, this is a higher level of debt than the average (55.8%)
64.9% - Mundibiopharma Limited
55.8% - Industry AVG
mundibiopharma limited Credit Report and Business Information
Mundibiopharma Limited Competitor Analysis
Perform a competitor analysis for mundibiopharma limited by selecting its closest rivals and benchmarking them against 12 key performance metrics.
mundibiopharma limited Ownership
MUNDIBIOPHARMA LIMITED group structure
Mundibiopharma Limited has no subsidiary companies.
Ultimate parent company
MUNDIBIOPHARMA LIMITED
09273949
mundibiopharma limited directors
Mundibiopharma Limited currently has 2 directors. The longest serving directors include Mr Bryan Lea (Aug 2015) and Mr Stephen Jamieson (Feb 2019).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Bryan Lea | England | 62 years | Aug 2015 | - | Director |
| Mr Stephen Jamieson | England | 66 years | Feb 2019 | - | Director |
MUNDIBIOPHARMA LIMITED financials
Mundibiopharma Limited's latest turnover from December 2022 is £232.8 million and the company has net assets of £84.5 million. According to their latest financial statements, Mundibiopharma Limited has 6 employees and maintains cash reserves of £17 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | |
|---|---|---|---|---|---|---|---|---|
| Turnover | 232,804,711 | 259,760,506 | 285,561,890 | 316,177,965 | 277,485,276 | 237,150,111 | 221,122,896 | 0 |
| Other Income Or Grants | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost Of Sales | 178,972,964 | 219,384,962 | 222,494,455 | 262,421,440 | 211,216,588 | 220,889,928 | 203,327,489 | 0 |
| Gross Profit | 53,831,747 | 40,375,544 | 63,067,435 | 53,756,525 | 66,268,689 | 16,260,182 | 17,795,407 | 0 |
| Admin Expenses | -8,981,240 | 14,500,711 | 37,840,255 | 37,904,063 | 50,920,356 | 70,869,236 | 66,103,612 | 290,147 |
| Operating Profit | 62,812,987 | 25,874,833 | 25,227,180 | 15,852,462 | 15,348,333 | -54,609,054 | -48,308,205 | -290,147 |
| Interest Payable | 7,491,110 | 7,198,749 | 6,882,950 | 6,527,744 | 5,311,356 | 3,177,514 | 2,342,216 | 91,164 |
| Interest Receivable | 3,228,854 | 2,931,254 | 2,869,789 | 1,253,668 | 0 | 2,568 | 7,012 | 0 |
| Pre-Tax Profit | 58,550,731 | 21,607,338 | 21,214,019 | 10,578,387 | 10,036,976 | -57,784,000 | -50,643,408 | -381,311 |
| Tax | -12,208,324 | -4,926,330 | -4,079,018 | -3,815,944 | 5,986,231 | 0 | 0 | 0 |
| Profit After Tax | 46,342,408 | 16,681,008 | 17,135,000 | 6,762,443 | 16,023,208 | -57,784,000 | -50,643,408 | -381,311 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Retained Profit | 46,342,408 | 16,681,008 | 17,135,000 | 6,762,443 | 16,023,208 | -57,784,000 | -50,643,408 | -381,311 |
| Employee Costs | 2,834,431 | 5,429,984 | 10,372,176 | 9,322,085 | 2,223,649 | 1,946,196 | 3,173,212 | 186,711 |
| Number Of Employees | 6 | 20 | 36 | 42 | 9 | 10 | 8 | 5 |
| EBITDA* | 62,812,987 | 25,874,833 | 25,227,180 | 15,852,462 | 15,771,252 | -54,609,054 | -48,308,205 | -290,147 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | |
|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 0 | 0 | 0 | 0 | 3,411,312 | 4,031,710 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 2,524,544 | 0 |
| Investments & Other | 94,053,636 | 94,380,682 | 85,751,193 | 60,086,417 | 0 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 94,053,636 | 94,380,682 | 85,751,193 | 60,086,417 | 3,411,313 | 4,031,711 | 2,524,544 | 0 |
| Stock & work in progress | 4,221 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Debtors | 40,202,473 | 35,225,894 | 44,456,858 | 61,608,267 | 40,747,042 | 50,225,895 | 16,253,506 | 0 |
| Group Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Misc Debtors | 89,673,424 | 39,190,006 | 33,478,815 | 13,268,428 | 17,171,195 | 5,761,011 | 19,507,363 | 31,607,643 |
| Cash | 16,956,550 | 10,794,796 | 7,914,560 | 5,509,715 | 1,400,726 | 14,528,982 | 11,310,484 | 196,353 |
| misc current assets | 0 | 0 | 0 | 39,663,949 | 6,984,515 | 0 | 0 | 0 |
| total current assets | 146,836,667 | 85,210,697 | 85,850,234 | 120,050,360 | 66,303,478 | 70,515,889 | 47,071,353 | 31,803,997 |
| total assets | 240,890,303 | 179,591,379 | 171,601,427 | 180,136,776 | 69,714,791 | 74,547,599 | 49,595,898 | 31,803,997 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 19,779,785 | 19,148,502 | 35,260,735 | 40,027,329 | 14,461,038 | 35,773,624 | 27,174,790 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 296,283 |
| other short term finances | 0 | 0 | 0 | 12,283,237 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 32,323,913 | 22,666,038 | 29,206,158 | 36,062,561 | 29,287,795 | 34,578,517 | 10,353,260 | 153,401 |
| total current liabilities | 52,103,698 | 41,814,541 | 64,466,894 | 88,373,128 | 43,748,834 | 70,352,142 | 37,528,050 | 449,684 |
| loans | 104,238,462 | 99,571,102 | 86,423,549 | 88,060,941 | 29,109,721 | 23,362,430 | 2,433,380 | 91,164 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total long term liabilities | 104,238,462 | 99,571,103 | 86,423,549 | 88,060,942 | 29,109,722 | 23,362,430 | 2,433,380 | 91,164 |
| total liabilities | 156,342,160 | 141,385,643 | 150,890,443 | 176,434,070 | 72,858,556 | 93,714,572 | 39,961,431 | 540,849 |
| net assets | 84,548,143 | 38,205,735 | 20,710,984 | 3,702,707 | -3,143,765 | -19,166,973 | 9,634,467 | 31,263,149 |
| total shareholders funds | 84,548,143 | 38,205,735 | 20,710,984 | 3,702,707 | -3,143,765 | -19,166,973 | 9,634,467 | 31,263,149 |
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Operating Profit | 62,812,987 | 25,874,833 | 25,227,180 | 15,852,462 | 15,348,333 | -54,609,054 | -48,308,205 | -290,147 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Amortisation | 0 | 0 | 0 | 0 | 422,919 | 0 | 0 | |
| Tax | -12,208,324 | -4,926,330 | -4,079,018 | -3,815,944 | 5,986,231 | 0 | 0 | 0 |
| Stock | 4,221 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors | 55,459,997 | -3,519,774 | 3,058,979 | 16,958,458 | 1,931,331 | 20,226,037 | 4,153,226 | 31,607,643 |
| Creditors | 631,283 | -16,112,233 | -4,766,594 | 25,566,291 | -21,312,586 | 8,598,835 | 27,174,790 | 0 |
| Accruals and Deferred Income | 9,657,875 | -6,540,120 | -6,856,403 | 6,774,766 | -5,290,722 | 24,225,257 | 10,199,859 | 153,401 |
| Deferred Taxes & Provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash flow from operations | 5,429,603 | 1,815,924 | 6,466,186 | 27,419,117 | -6,777,156 | -15,086,782 | -31,744,389 | |
| Investing Activities | ||||||||
| capital expenditure | 0 | 0 | 0 | 0 | 0 | -1,677,693 | -2,524,544 | 0 |
| Change in Investments | -327,046 | 8,629,489 | 25,664,777 | 60,086,417 | 0 | 0 | 0 | 0 |
| cash flow from investments | 327,046 | -8,629,489 | -25,664,777 | -60,086,417 | 0 | -1,677,693 | -2,524,544 | 0 |
| Financing Activities | ||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | -296,283 | 296,283 |
| Other Short Term Loans | 0 | 0 | -12,283,237 | 12,283,237 | 0 | 0 | 0 | 0 |
| Long term loans | 4,667,360 | 13,147,553 | -1,637,392 | 58,951,220 | 5,747,291 | 20,929,050 | 2,342,216 | 91,164 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| share issue | ||||||||
| interest | -4,262,256 | -4,267,495 | -4,013,161 | -5,274,076 | -5,311,356 | -3,174,946 | -2,335,204 | -91,164 |
| cash flow from financing | 405,104 | 9,693,801 | -18,060,512 | 66,044,410 | 435,935 | 46,736,664 | 28,725,455 | 31,940,743 |
| cash and cash equivalents | ||||||||
| cash | 6,161,753 | 2,880,236 | 2,404,844 | 4,108,990 | -13,128,257 | 3,218,498 | 11,114,130 | 196,353 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | 6,161,753 | 2,880,236 | 2,404,844 | 4,108,990 | -13,128,257 | 3,218,498 | 11,114,130 | 196,353 |
P&L
December 2022turnover
232.8m
-10%
operating profit
62.8m
+143%
gross margin
23.2%
+48.77%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2022net assets
84.5m
+1.21%
total assets
240.9m
+0.34%
cash
17m
+0.57%
net assets
Total assets minus all liabilities
mundibiopharma limited company details
company number
09273949
Type
Private limited with Share Capital
industry
46460 - Wholesale of pharmaceutical goods
incorporation date
October 2014
age
10
accounts
Full Accounts
ultimate parent company
previous names
N/A
incorporated
UK
address
unit 196 cambridge science park, milton road, cambridge, CB4 0AB
last accounts submitted
December 2022
mundibiopharma limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to mundibiopharma limited.
mundibiopharma limited Companies House Filings - See Documents
| date | description | view/download |
|---|
